Caldera Medical, a women’s health devices company, has acquired UVision 360, developer of the Luminelle hysteroscopy and cystoscopy systems.
 
Caldera said the acquisition fortifies its minimally invasive solutions, particularly in advanced hysteroscopy. This broadens its portfolio for diagnosis and treatment of polyps, fibroids, and intrauterine pathology.
 
The Luminelle system offers a cost-effective alternative for diagnostic and therapeutic hysteroscopy, the company said. It’s compatible with existing surgical workflows, making it an option for surgeons seeking minimally invasive, efficient solutions to boost precision and recovery time.
 
For gynecologic surgeons, the combination of Caldera’s Benesta product line with Luminelle offers enhanced procedural capabilities, improving clinical outcomes for a wide range of intrauterine treatments, including polypectomies, biopsies, and fibroid resections in both office-based and surgical environments.
 
 “We are excited to integrate LUMINELLE’s technology into Caldera Medical’s growing portfolio,” said Bryon Merade, CEO of Caldera Medical. “This acquisition strengthens our commitment to offering gynecologic surgeons state-of-the-art tools that streamline hysteroscopic procedures while enhancing patient safety and clinical outcomes.”
 
“I’m thrilled to join the talented team at Caldera Medical to expand the commercial reach of the LUMINELLE portfolio,” added Erich Dreyer, co-founder and engineer behind the Luminelle technology. “I’m particularly excited about our new LUMINELLE Bx product, which allows physicians to achieve a more accurate and precise diagnosis through its novel on-demand biopsy technology with integrated visualization. With Caldera’s commercial infrastructure and investment in women’s health, we will be able to provide both physicians and patients with a solution to the flawed uterine disease diagnosis market dominated by inaccurate blind biopsies.”